Sign inCreate account

Report workspace tools

NCT02073916COMPLETEDanonymous

Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients

Sponsor

Source record

Jenny C. Chang, MD

Phase

Source record

Phase Ib

Modality

AI-normalized

small molecule

Target

AI-normalized

HER2-positive metastatic breast cancer

Indication / condition

AI-normalized

Metastatic Breast Cancer

Intervention

Source record

T-DM1, Lapatinib, Abraxane

Source & freshness

Source record

NCT ID

NCT02073916

Original source

ClinicalTrials.gov

Source last updated

Apr 16, 2019

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02073916

Title

Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients

Sponsor

Jenny C. Chang, MD

Status

COMPLETED

Phase

Phase Ib

Condition raw

Metastatic Breast Cancer

Condition normalized

Metastatic Breast Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

T-DM1, Lapatinib, Abraxane

Target normalized

HER2-positive metastatic breast cancer

Interventions

T-DM1, Lapatinib, Abraxane

Public preview

Source record

This clinical trial evaluated the safety and tolerability of a combination therapy involving trastuzumab emtansine (T-DM1), Lapatinib, and Abraxane in patients with metastatic HER2-positive breast cancer. The study was conducted by The Methodist Hospital Research Institute and completed in December 2018 with 24 participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02073916

Status

COMPLETED

Phase

Phase Ib

Sponsor

Jenny C. Chang, MD

Executive brief

Investment-Ready Snapshot

This clinical trial evaluated the safety and tolerability of a combination therapy involving trastuzumab emtansine (T-DM1), Lapatinib, and Abraxane in patients with metastatic HER2-positive breast cancer. The study was conducted by The Methodist Hospital Research Institute and completed in December 2018 with 24 participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 16, 2019
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02073916

Indication

Metastatic Breast Cancer

Modality

small molecule

Target

HER2-positive metastatic breast cancer

Intervention

T-DM1, Lapatinib, Abraxane

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.